7.5 C
Glasgow
Monday, February 9, 2026
spot_img

More News

Johnson & Johnson prostate cancer drug receives CHMP positive opinion

Jim Cornall -
Johnson & Johnson has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines...

Breakthru Medicine emerges from stealth to develop cancer drugs

Jim Cornall -
Breakthru Medicine has emerges from stealth with the close of a $60m Series A financing round following a prior...

FDA Rare Pediatric Disease designation for mucopolysaccharidosis Type II treatment

Jim Cornall -
Immusoft of CA, a clinical-stage biotechnology company pioneering engineered B cell therapies, has announced that the U.S. Food and...

CIRM approves $100m plan to accelerate genetic therapies for patients with rare diseases

Jim Cornall -
The California Institute for Regenerative Medicine (CIRM) has approved a new funding programme to accelerate therapies for rare diseases,...

Researchers develop more reliable platform to test antibody medicines

Jim Cornall -
An international research consortium, led by scientists at VIB and UGent in Belgium, has developed a new platform that...

Positive topline results from acne study

Jim Cornall -
Ascletis Pharma Inc. has announced positive topline results from its phase III open-label study evaluating denifanstat (ASC40), a first-in-class,...

Sarbecovirus vaccine trial starts

Jim Cornall -
SK bioscience has announced the initiation of a global phase 1/2 clinical trial in Australia for GBP511, a vaccine...

Vetter Pharma to build new manufacturing site in Germany

Jim Cornall -
German CDMO Vetter has confirmed its plans to build a production facility in the Saarland region of southwest Germany. Construction...

New dementia treatment strategy proposed

Jim Cornall -
Conventional treatments of Alzheimer’s disease, one of the most common forms of dementia, have been largely focused on targeting...

FDA IND clearance for Trace Biosciences’ nerve-specific imaging agent

Jim Cornall -
Trace Biosciences, Inc. has announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug...

Lilly injectable medicine and device manufacturing facility to be built in Pennsylvania

Jim Cornall -
Eli Lilly and Company has announced plans to invest more than $3.5bn in a new manufacturing facility in the...

A broken DNA repair tool accelerates aging

Jim Cornall -
Although DNA is tightly packed and protected within the cell nucleus, it is constantly threatened by damage from normal...

Base to Base biotech podcast 44: Treating breast cancer and how a CDMO and immuno-oncology company collaborate

Jim Cornall -
This week, we chat with Pan Cancer T CEO Dr. Rachel Abbott, about – among other things – triple-negative...

Two-faced nanoparticles help antibiotics treat resistant bacteria

Jim Cornall -
In the global battle against antimicrobial resistance (AMR), an international research team has unveiled what it says is a...

Resolve M Therapeutics exits from stealth

Jim Cornall -
Resolve M Therapeutics, Inc. has announced its exit from stealth. Resolve M was created through a strategic collaboration between...

New cancer treatment options through expanding ADC payload spectrum

Jim Cornall -
Tubulis has published preclinical proof-of-concept data for its novel Alco5 conjugation platform in Nature Communications. The paper, Expanding the payload...

Why tumours become aggressive and genetically unstable

Jim Cornall -
A new study shows that cancer damages its own DNA by pushing key genes to work too hard. Cancer cells...

DIA launches platform to boost drug development

Jim Cornall -
The Drug Information Association (DIA) has launched DIA ASCENT, a new global platform designed to support early-stage biotechnology drug...

Nanoscope boosts retina gene therapy in Japan

Jim Cornall -
Nanoscope Therapeutics, Inc., a biotechnology company developing disease-agnostic therapies for vision loss caused by retinal degeneration, has announced that...

Ouro Medicines receives Fast Track Designation for gamgertamig

Jim Cornall -
Ouro Medicines, which is developing immune reset therapeutics for people living with chronic, immune-mediated diseases, has announced that gamgertamig,...

Infinitopes raises more funds for precision cancer vaccine

Jim Cornall -
Infinitopes, a clinical-stage cancer vaccine biotechnology company, has completed the second close of its seed financing round, securing an...

Deeptech Digest is your guide to what's new in at the cutting edge of science technology. A bit of artificial intelligence, some biotech, and all the news and latests developments in the field. If it's deeptech, it's in Deeptech Digest!

Contact us: jim@deeptechdigest.com

© 2023 Ayr Coastal Media